Navigation Links
Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
Date:1/13/2010

In the agreement between the two Toronto-area companies, Microbix will maintain sales and marketing functions while Therapure will manage manufacturing, distribution and product development

Toronto, Ontario (PRWEB) January 13, 2010 -- Microbix Biosystems Inc. (MBX:TSX) a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

The partnership will significantly expand the portfolio of products Microbix will offer its customers and increase capacity by leveraging Therapure’s state-of-the-art, commercial scale manufacturing facility. Under terms of the agreement, Microbix will maintain the sales and marketing functions for the water-based program, while Therapure will manage manufacturing and product development operations. The products will remain under the Microbix brand. Further financial details of the transaction were not made public.

Microbix, whose water-based product sales have nearly doubled each year since 2006, will benefit from the agreement due to Therapure’s large manufacturing capacity, its R&D expertise as well as its testing, filling, packaging and shipping services. Therapure will gain by tapping into Microbix’ established market position as a leading water-based products supplier to the North American pharmaceutical industry.

Microbix CEO William J. Gastle said, “Therapure’s capabilities will enable Microbix to expand our product line and market share of the growing water-based business in North America. Our partnership will enable us to provide a complete portfolio of water-based products which will drive sales higher while increasing customer satisfaction.”

“Water-based products are an important part of Microbix’ core business, which has been growing by more than 20% for the past six years. Our core business also represents significant contributions to our total revenue,” Gastle added.

Thomas Wellner, President and CEO of Therapure said, “Therapure Biopharma is excited to partner with another Canadian-based biotechnology company. This opportunity enables Therapure to leverage our large water and buffer manufacturing capacity and our Health Canada licensed aseptic filling capabilities.”

The immediate result of the Microbix-Therapure agreement will be the launch of Microbix 22™, a new 22% alcohol and water-for-injection (WFI) pre-mixed used for chromatography column storage. Mixing concentrated alcohol with water can be dangerous and many customers would rather purchase the product premixed and avoid the risks. Additionally, the partnership will be able to manufacture custom buffers and media to recipes provided by customers.

About Microbix:
Microbix specializes in the development of biological technologies and commercializing them through global partners. The Company has intellectual property in large market biotherapeutic drugs, vaccine technologies and animal reproduction technologies. Established in 1988, Microbix is headquartered in Toronto.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its’ clients. Therapure’s Health Canada licensed 130,000 sq.ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

This press release contains forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to , develop and commercialize new products on a timely basis, non-adoption of products by new customers, resistance to business model for commercialization and implementation; risks associated with commercializing new products; and risks associated with outsourcing production including control over costs, quality, quantity and timeliness of delivery of products. These forward-looking statements represent the Companies’ judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. SEDAR: 00004220E

Contacts:

Microbix
Please visit: www.microbix.com
Or contact:
William J. Gastle, CEO, (416) 234-1624 x 230;
James Long, CFO, (416) 234-1624 x 265

Therapure
Please visit: www.therapurebio.com
Or contact:
Thomas Wellner, President and CEO, (905) 286-6204
Raj Puri, Director Business Development, (905) 286-6232
ceo (at) therapurebio (dot) com

###

Read the full story at http://www.prweb.com/releases/2010/01/prweb3438474.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
2. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
3. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
4. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
5. Seven More Biopharmaceutical Research Companies Join PhRMA
6. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
7. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
8. Leading Biopharmaceutical Company Selects Stimar for Code of Conduct Regulation Training
9. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
10. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
11. aTyr Pharma to Present at Japan Biopharma Partnering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
(Date:3/24/2017)... ... 24, 2017 , ... Judy Buchanan, co-owner of Serenity Natural ... Judy says, “I am passionate about sharing Reiki as a holistic, complementary therapy ... challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys Medical ...
(Date:3/24/2017)... ... 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks at ... his life to the fullest, as God intended. “The Adventures of Joey, The Dog ... and grandmother pursuing her passion for writing, especially about truth and human behavior. , ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... PUNE, India , March 24, 2017 Abdominal ... to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% from 2016 ... revenue, and is projected to dominate the market during the study period. ... ... Logo ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The global wound care market was worth $24,482.9 million in 2015 ... 2016-2022 Among the various wound care products type, the advanced ... in 2015. Among the various applications, surgical wound segment held the largest ...
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
Breaking Medicine Technology: